Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program

Gurdeep Singh; Matthew Krauthamer; Meghan Bjalme-Evans

doi:doi:10.11648/j.ijde.20210604.17

| Peer-Reviewed

Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program

Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans

Published in International Journal of Diabetes and Endocrinology (Volume 6, Issue 4)

Received: 27 November 2021 Accepted: 14 December 2021 Published: 24 December 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Background: The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program was a phase III, multinational, multicenter program comprising 13 trials. Objective: Investigate the safety and efficacy of once-weekly, subcutaneous semaglutide versus other antidiabetic comparators, both as a monotherapy and in addition to other antidiabetic medications. Methods: This review summarizes the 10 trials that comprise the bulk of the evidence which led to FDA approval of semaglutide as an antidiabetic drug. Most articles were accessed via the National Center for Biotechnology Information database using pertinent search terms. Results: Semaglutide 0.5 mg and 1 mg weekly subcutaneous injection led to HA1c reductions by 1.1%–1.5% and 1.5%–1.8%, respectively. Bodyweight reduction with 0.5 mg and 1 mg dose of semaglutide ranged from 3.47–4.6 kg and 4.53–6.5 kg, respectively. SUSTAIN 6, in particular, found cardiovascular risk factor benefits, including the rate of nonfatal myocardial infarction, cardiovascular death and nonfatal strokes in high-risk patients correlated with the use of semaglutide in patients with type 2 diabetes. Conclusions: Semaglutide is superior to other glucagon-like peptide-1 receptor agonists, including exenatide, dulaglutide, and liraglutide in hemoglobin A1c reduction. It is also helpful for chronic weight loss and has cardioprotective effects.

Published in	International Journal of Diabetes and Endocrinology (Volume 6, Issue 4)
DOI	10.11648/j.ijde.20210604.17
Page(s)	167-174
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Semaglutide, SUSTAIN, Incretin Therapy, GLP-1 Analog, Antidiabetic Therapy, Type Two Diabetes

References

[1]	Nauck MA, Petrie JR, Sesti G, Mannucci E, Courrèges JP, Lindegaard ML, et al. A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes. Diabetes Care. 2016; 39: 231–241. https://doi.org/10.2337/dc15-0165.
[2]	Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Diabetes Obes Metab. 2020; 22: 1263–1277. https://doi.org/10.1111/dom.14054.
[3]	Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev. 2014; 30: 354–371. https://doi.org/10.1002/dmrr.2501.
[4]	Buse JB, Wexler DJ, Tsapas A, Rossing P, Mingrone G, Mathieu C, et al. 2019 update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2020; 63: 221–228. https://doi.org/10.4158/EP161682.CS.
[5]	Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020; 26: 107–139. https://doi.org/10.4158/CS-2019-0472.
[6]	Aroda VR, Bain SC, Cariou B, Piletič M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomized, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5: 355–566. https://doi.org/10.1016/S2213-8587(17)30085-2.
[7]	Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016; 18: 203–216 https://doi.org/10.1111/dom.12591.
[8]	Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016; 375: 1834–1844. https://doi.org/10.1056/NEJMoa1607141.
[9]	Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018; 1032291–1032301. https://doi.org/10.1210/jc.2018-00070.
[10]	Sorli C, Harashima S, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017; 5: 251–260. https://doi.org/10.1016/S2213-8587(17)30013-X.
[11]	Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019; 7: 356–367. https://doi.org/10.1016/S2213-8587(19)30066-X.
[12]	Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide XR in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018; 41: 258–266. https://doi.org/10.2337/dc17-0417.
[13]	Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a randomised trial. Lancet Diabetes Endocrinol. 2017; 5: 341–354. https://doi.org/10.1210/jc.2018-00070.
[14]	Capehorn MS, Catarig AM, Furberg JK, Janez A, Price HC, et al. Efficacy and safety of once-weekly semaglutide 1.0 mg vs. once-daily liraglutide 1.2 mg as add-on to 1-3 antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020; 46: 100–109. https://doi.org/10.1016/j.diabet.2019.101117.
[15]	Lingvay I, Catarig A, Frias JP, Kumar H, Lausvig NL, le Roux CW, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019; 7: 834–844. https://doi.org/10.1016/S2213-8587(19)30311-0.
[16]	Pratley RE, Aroda VR, Lingvay I, Lüdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once-weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018; 6: 275–286. https://doi.org/10.1016/S2213-8587(18)30024-X.
[17]	American Diabetes Association. Glycemic targets: Standards of medical care in diabetes - 2020. Diabetes Care. 2020; 43: S66–S76. https://doi.org/10.2337/dc20-S006.
[18]	Van Gaal L, Scheen A. Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care. 2015; 38: 1161–1172. https://doi.org/10.2337/dc14-1630.
[19]	Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013; 2013: 653789. https://doi.org/10.1155/2013/653789.
[20]	Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, et al. Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017; 16: 6. https://doi.org/10.1186/s12933-016-0490-6.
[21]	Wirth A. [Anti-diabetic drugs. Weight reduction as a favorable side effect]. Internist (Berl). 2011; 52: 451–452. https://doi.org/10.1007/s00108-011-2811-x.
[22]	Iglay K, Hannachi H, Joseph Howie P, Xu J, Li X, Engel SS, et al. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus. Curr Med Res Opin. 2016; 32: 1243–1252. https://doi.org/10.1185/03007995.2016.1168291.
[23]	Isaacs D, Prasad-Reddy L, Srivastava SB. Role of glucagon-like peptide 1 receptor agonists in management of obesity. Am J Health Syst Pharm. 2016; 73: 1493–1507. https://doi.org/10.2146/ajhp150990.
[24]	Shantha GP, Kumar AA, Kahan S, Cheskin LJ. Association between glycosylated hemoglobin and intentional weight loss in overweight and obese patients with type 2 diabetes mellitus: a retrospective cohort study. Diabetes Educ. 2012; 38: 417–426.https://doi.org/10.1177/0145721712443293.
[25]	Malin SK, Kashyap SR. Effects of metformin on weight loss: potential mechanisms. Curr Opin Endocrinol Diabetes Obes. 2014; 21: 323–329.https://doi.org/10.1097/MED.0000000000000095.
[26]	Balkau B, Home PD, Vincent M, Marre M, Freemantle N. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care. 2014; 37: 2108–2113. https://doi.org/10.2337/dc13-3010.
[27]	Miles KE and Kerr JL. Semaglutide for the treatment of type 2 diabetes mellitus. J Pharm Technol. 2018; 34: 281–289. https://doi.org/10.1177/8755122518790925.
[28]	Røder ME. Clinical potential of treatment with semaglutide in type 2 diabetes patients. Drugs in Context. 2019; 8: 212585. https://doi.org/10.7573/dic.212585.
[29]	Goldenberg RM, Steen O. Semaglutide: Review and place in therapy for adults with type 2 diabetes. Can J Diabetes. 2019; 43: 136–145. https://doi: 10.1016/j.jcjd.2018.05.008.
[30]	DeVries JH, Desouza C, Bellary S, Unger J, Hansen OK, Zacho J, et al. Achieving glycaemic control without weight gain, hypoglycemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. Diabetes Obes Metab. 2018; 20: 2426–2434. https://doi: 10.1111/dom.13396.

Cite This Article

Plain Text BibTeX RIS

APA Style

Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans. (2021). Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program. International Journal of Diabetes and Endocrinology, 6(4), 167-174. https://doi.org/10.11648/j.ijde.20210604.17

Copy | Download

ACS Style

Gurdeep Singh; Matthew Krauthamer; Meghan Bjalme-Evans. Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program. Int. J. Diabetes Endocrinol. 2021, 6(4), 167-174. doi: 10.11648/j.ijde.20210604.17

Copy | Download

AMA Style

Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans. Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program. Int J Diabetes Endocrinol. 2021;6(4):167-174. doi: 10.11648/j.ijde.20210604.17

Copy | Download

@article{10.11648/j.ijde.20210604.17,
  author = {Gurdeep Singh and Matthew Krauthamer and Meghan Bjalme-Evans},
  title = {Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {6},
  number = {4},
  pages = {167-174},
  doi = {10.11648/j.ijde.20210604.17},
  url = {https://doi.org/10.11648/j.ijde.20210604.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20210604.17},
  abstract = {Background: The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program was a phase III, multinational, multicenter program comprising 13 trials. Objective: Investigate the safety and efficacy of once-weekly, subcutaneous semaglutide versus other antidiabetic comparators, both as a monotherapy and in addition to other antidiabetic medications. Methods: This review summarizes the 10 trials that comprise the bulk of the evidence which led to FDA approval of semaglutide as an antidiabetic drug. Most articles were accessed via the National Center for Biotechnology Information database using pertinent search terms. Results: Semaglutide 0.5 mg and 1 mg weekly subcutaneous injection led to HA1c reductions by 1.1%–1.5% and 1.5%–1.8%, respectively. Bodyweight reduction with 0.5 mg and 1 mg dose of semaglutide ranged from 3.47–4.6 kg and 4.53–6.5 kg, respectively. SUSTAIN 6, in particular, found cardiovascular risk factor benefits, including the rate of nonfatal myocardial infarction, cardiovascular death and nonfatal strokes in high-risk patients correlated with the use of semaglutide in patients with type 2 diabetes. Conclusions: Semaglutide is superior to other glucagon-like peptide-1 receptor agonists, including exenatide, dulaglutide, and liraglutide in hemoglobin A1c reduction. It is also helpful for chronic weight loss and has cardioprotective effects.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program
AU  - Gurdeep Singh
AU  - Matthew Krauthamer
AU  - Meghan Bjalme-Evans
Y1  - 2021/12/24
PY  - 2021
N1  - https://doi.org/10.11648/j.ijde.20210604.17
DO  - 10.11648/j.ijde.20210604.17
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 167
EP  - 174
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20210604.17
AB  - Background: The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program was a phase III, multinational, multicenter program comprising 13 trials. Objective: Investigate the safety and efficacy of once-weekly, subcutaneous semaglutide versus other antidiabetic comparators, both as a monotherapy and in addition to other antidiabetic medications. Methods: This review summarizes the 10 trials that comprise the bulk of the evidence which led to FDA approval of semaglutide as an antidiabetic drug. Most articles were accessed via the National Center for Biotechnology Information database using pertinent search terms. Results: Semaglutide 0.5 mg and 1 mg weekly subcutaneous injection led to HA1c reductions by 1.1%–1.5% and 1.5%–1.8%, respectively. Bodyweight reduction with 0.5 mg and 1 mg dose of semaglutide ranged from 3.47–4.6 kg and 4.53–6.5 kg, respectively. SUSTAIN 6, in particular, found cardiovascular risk factor benefits, including the rate of nonfatal myocardial infarction, cardiovascular death and nonfatal strokes in high-risk patients correlated with the use of semaglutide in patients with type 2 diabetes. Conclusions: Semaglutide is superior to other glucagon-like peptide-1 receptor agonists, including exenatide, dulaglutide, and liraglutide in hemoglobin A1c reduction. It is also helpful for chronic weight loss and has cardioprotective effects.
VL  - 6
IS  - 4
ER  -

Copy | Download

Author Information

Gurdeep Singh

Our Lady of Lourdes Memorial Hospital, Binghamton, New York, USA
Matthew Krauthamer

Our Lady of Lourdes Memorial Hospital, Binghamton, New York, USA
Meghan Bjalme-Evans

Our Lady of Lourdes Memorial Hospital, Binghamton, New York, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans. (2021). Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program. International Journal of Diabetes and Endocrinology, 6(4), 167-174. https://doi.org/10.11648/j.ijde.20210604.17

Copy | Download

ACS Style

Gurdeep Singh; Matthew Krauthamer; Meghan Bjalme-Evans. Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program. Int. J. Diabetes Endocrinol. 2021, 6(4), 167-174. doi: 10.11648/j.ijde.20210604.17

Copy | Download

AMA Style

Gurdeep Singh, Matthew Krauthamer, Meghan Bjalme-Evans. Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program. Int J Diabetes Endocrinol. 2021;6(4):167-174. doi: 10.11648/j.ijde.20210604.17

Copy | Download

@article{10.11648/j.ijde.20210604.17,
  author = {Gurdeep Singh and Matthew Krauthamer and Meghan Bjalme-Evans},
  title = {Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program},
  journal = {International Journal of Diabetes and Endocrinology},
  volume = {6},
  number = {4},
  pages = {167-174},
  doi = {10.11648/j.ijde.20210604.17},
  url = {https://doi.org/10.11648/j.ijde.20210604.17},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20210604.17},
  abstract = {Background: The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program was a phase III, multinational, multicenter program comprising 13 trials. Objective: Investigate the safety and efficacy of once-weekly, subcutaneous semaglutide versus other antidiabetic comparators, both as a monotherapy and in addition to other antidiabetic medications. Methods: This review summarizes the 10 trials that comprise the bulk of the evidence which led to FDA approval of semaglutide as an antidiabetic drug. Most articles were accessed via the National Center for Biotechnology Information database using pertinent search terms. Results: Semaglutide 0.5 mg and 1 mg weekly subcutaneous injection led to HA1c reductions by 1.1%–1.5% and 1.5%–1.8%, respectively. Bodyweight reduction with 0.5 mg and 1 mg dose of semaglutide ranged from 3.47–4.6 kg and 4.53–6.5 kg, respectively. SUSTAIN 6, in particular, found cardiovascular risk factor benefits, including the rate of nonfatal myocardial infarction, cardiovascular death and nonfatal strokes in high-risk patients correlated with the use of semaglutide in patients with type 2 diabetes. Conclusions: Semaglutide is superior to other glucagon-like peptide-1 receptor agonists, including exenatide, dulaglutide, and liraglutide in hemoglobin A1c reduction. It is also helpful for chronic weight loss and has cardioprotective effects.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Semaglutide as an Antidiabetic Medication: A Summary of the Evidence from the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes Clinical Trial Program
AU  - Gurdeep Singh
AU  - Matthew Krauthamer
AU  - Meghan Bjalme-Evans
Y1  - 2021/12/24
PY  - 2021
N1  - https://doi.org/10.11648/j.ijde.20210604.17
DO  - 10.11648/j.ijde.20210604.17
T2  - International Journal of Diabetes and Endocrinology
JF  - International Journal of Diabetes and Endocrinology
JO  - International Journal of Diabetes and Endocrinology
SP  - 167
EP  - 174
PB  - Science Publishing Group
SN  - 2640-1371
UR  - https://doi.org/10.11648/j.ijde.20210604.17
AB  - Background: The Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) clinical trial program was a phase III, multinational, multicenter program comprising 13 trials. Objective: Investigate the safety and efficacy of once-weekly, subcutaneous semaglutide versus other antidiabetic comparators, both as a monotherapy and in addition to other antidiabetic medications. Methods: This review summarizes the 10 trials that comprise the bulk of the evidence which led to FDA approval of semaglutide as an antidiabetic drug. Most articles were accessed via the National Center for Biotechnology Information database using pertinent search terms. Results: Semaglutide 0.5 mg and 1 mg weekly subcutaneous injection led to HA1c reductions by 1.1%–1.5% and 1.5%–1.8%, respectively. Bodyweight reduction with 0.5 mg and 1 mg dose of semaglutide ranged from 3.47–4.6 kg and 4.53–6.5 kg, respectively. SUSTAIN 6, in particular, found cardiovascular risk factor benefits, including the rate of nonfatal myocardial infarction, cardiovascular death and nonfatal strokes in high-risk patients correlated with the use of semaglutide in patients with type 2 diabetes. Conclusions: Semaglutide is superior to other glucagon-like peptide-1 receptor agonists, including exenatide, dulaglutide, and liraglutide in hemoglobin A1c reduction. It is also helpful for chronic weight loss and has cardioprotective effects.
VL  - 6
IS  - 4
ER  -

Copy | Download